Omega-3
Substance type: Essential long-chain polyunsaturated fatty acid (LC-PUFA) Key molecules: EPA (eicosapentaenoic acid, 20:5 n-3) · DHA (docosahexaenoic acid, 22:6 n-3) · DPA (docosapentaenoic acid, 22:5 n-3) Evidence grade: Strong for anti-inflammatory and CV risk reduction in specific populations; null for primary prevention, MPS stimulation, and cognitive enhancement in healthy adults Batch: batch-25-2026-04-05
TL;DR
Omega-3 (EPA/DHA) is most reliably useful for raising the Omega-3 Index above 8% (CV risk reduction), reducing inflammation at ≥1–3 g/day, and as an NSAID-sparing agent in rheumatoid arthritis at ≥2.7 g/day. It does not stimulate muscle protein synthesis directly. The 2:1 EPA:DHA ratio is marketing, not evidence. Total daily dose is the evidence-based lever. At ≥4 g/day, a modest increase in atrial fibrillation risk emerges. The best biometric to track is the Omega-3 Index.
Why it matters for Vitals
- Inflammation resolution is a core Vitals domain, and omega-3 is one of the few supplements with a mechanistically distinct pro-resolution pathway via Specialized Pro-Resolving Mediators
- The Omega-3 Index is a consumer-accessible finger-prick blood test that directly reflects membrane EPA+DHA content — making supplementation progress measurable
- HRV improvement is population-dependent — most plausible in people with elevated baseline inflammation or autonomic dysregulation; healthy adults with replete omega-3 status are unlikely to see wearable-detectable HRV changes
- Omega-3 + resistance training improves strength in older adults via a synergistic, non-MPS mechanism — relevant for Vitals sarcopenia coaching
- High-dose omega-3 (≥4 g/day) creates an AFib detection tradeoff: the same wearables that surface HRV benefits can detect the arrhythmic signal emerging from high-dose supplementation
Key facts
| Claim | Verdict | Evidence |
|---|---|---|
| Raises Omega-3 Index >8% | Confirmed | 1.5–2.25 g/day TG form; 2.25–3.25 g/day EE form |
| Anti-inflammatory at ≥1–3 g/day | Confirmed | CRP, IL-6, TNF-α reduction; 96-trial meta-analysis PMID:41568426 |
| NSAID-sparing in RA at ≥2.7 g/day | Confirmed | PMID:22835600 |
| Does NOT stimulate MPS directly | Confirmed | PMID:38777807, SMD=0.03, P=0.89 |
| + RET improves strength in older adults | Supported | PMID:38777432; mechanism is not MPS stimulation |
| 2:1 EPA:DHA ratio is optimal | Debunked | Total dose > ratio; PMID:33418065 |
| REDUCE-IT (4g pure EPA) CV benefit | Confirmed | 25% RRR in MACE in statin-treated high-TG patients |
| STRENGTH trial (4g EPA+DHA) null | Confirmed | Futility stop; corn oil placebo |
| VITAL trial primary prevention | Null | HR 0.92, P>0.05; not recommended for primary CVD prevention |
| No increased surgical bleeding | Confirmed | PMID:28552094; do NOT discontinue before surgery |
| High-dose (≥4g) increases AFib risk | Confirmed | STRENGTH, REDUCE-IT signal; dose-dependent |
| Algae oil ≈ fish oil at matched dose | Supported | PMC:12524788 |
| rTAG form has best bioavailability | Confirmed | 124% vs natural fish oil; PMID:20638827 |
| HRV benefit in healthy adults | Contested | Benefits population-specific; elevated inflammation or dysregulation required |
| IFOS 5-star = purity quality marker | Confirmed | Most rigorous third-party verification available |
| Fish allergy | Contraindicated | Anaphylaxis risk from fish protein traces; PMID:18926060 |
Mechanism summary
Primary pathways
1. Specialized Pro-Resolving Mediators (SPMs) EPA and DHA are enzymatically converted to SPMs — resolvins (E-series from EPA, D-series from DHA), protectins/neuroprotectins, and maresins. These actively resolve inflammation rather than suppressing it. This is mechanistically distinct from NSAIDs (COX inhibition) and steroids (glucocorticoid receptor). See Specialized Pro-Resolving Mediators.
2. Arachidonic Acid (AA) competition EPA/DHA compete with omega-6 AA for incorporation into cell membrane phospholipids. A lower membrane AA:EPA+DHA ratio shifts eicosanoid production away from pro-inflammatory 2-series prostaglandins and leukotrienes toward less inflammatory 3-series and 5-series mediators. Minimum dose to shift the ratio meaningfully: ~1–2 g/day EPA+DHA.
Form differences
| Form | Bioavailability | Notes |
|---|---|---|
| rTAG (re-esterified triglyceride) | 124% vs natural FO | Best choice; best bioavailability |
| FFA (free fatty acid) | 91% vs natural FO | No food effect |
| Natural TG | 100% reference | Standard fish oil |
| EE (ethyl ester) | 73% vs natural FO | Requires high-fat meal for adequate absorption |
| PL (phospholipid, krill) | Higher per-capsule incorporation but lower absolute dose | Plausible alternative; no outcome RCTs |
Pharmacokinetics
- Plasma half-life EPA (phospholipids): ~1.97 days; (cholesteryl esters): ~3.27 days
- Plasma steady state: ~4 weeks
- RBC Omega-3 Index steady state: 12–16 weeks — this is why testing at 4 months is the evidence-based window
What the current evidence suggests
Cardiovascular
- REDUCE-IT (4 g/day pure EPA ethyl ester, statin-treated high-TG patients): 25% RRR in MACE — Confirmed but not generalizable to OTC fish oil
- STRENGTH (4 g/day EPA+DHA FFA, similar population): null — suggests DHA may attenuate EPA’s CV benefit, or formulation matters
- VITAL (primary prevention, 1 g/day): null result — omega-3 is not recommended for primary CVD prevention in the general population
Inflammation and autoimmune
- Consistent CRP, IL-6, TNF-α reduction at 1–3 g/day EPA+DHA in meta-analyses
- Rheumatoid arthritis: ≥2.7 g/day produces NSAID-sparing effect — Confirmed
- No evidence for anti-inflammatory benefit at <1 g/day in healthy adults
Muscle and strength
- Direct MPS stimulation: NO-EFFECT (PMID:38777807, SMD=0.03, P=0.89, k=6 RCTs)
- Omega-3 + resistance training does improve strength in older adults — mechanism likely neural/mitochondrial, not anabolic
HRV and autonomic function
- Benefits are population-dependent: children with obesity, post-MI patients, and adults with elevated inflammation show improvement
- Healthy adults with replete omega-3 status: no consistent HRV benefit
- Mechanism: baroreflex sensitization + reduced inflammatory cytokine suppression of parasympathetic tone
Cognitive function
- No improvement in healthy adults — No-Effect (PMID:35338847)
- The OmegAD study confirmed BBB penetration (CSF EPA increases), but functional cognitive benefit in non-deficient populations is not established
Exercise performance
- Some improvements in running economy and VO2max at 2–4 g/day in athletic/military populations — Reported but limited and not a primary indication
Likely wearable / Vitals relevance
What wearables may detect
| Metric | Signal direction | Confidence |
|---|---|---|
| Resting HR | Mild reduction | Moderate; meta-analyses show effect |
| HRV (rmSSD, sdNN) | Improvement in inflamed populations | Low-Moderate; population-dependent |
| Sleep quality/architecture | Improvement (74% of studies) | Moderate |
| Post-exercise HRV recovery | Enhanced recovery signal | Low-Moderate; inferential |
| AFib detection | Increased risk at ≥4 g/day | High for the risk; wearables detect the signal |
What wearables cannot measure
| Metric | Alternative |
|---|---|
| CRP, IL-6, TNF-α | Omega-3 Index finger-prick test (consumer-accessible) |
| Platelet aggregation / bleeding time | Self-reported bruising |
| Membrane AA:EPA+DHA ratio | Omega-3 Index |
Coaching implications
- Baseline and 4-month Omega-3 Index test is the evidence-based way to verify omega-3 supplementation is working — this is the single most actionable biometric for omega-3
- Healthy users with already-replete omega-3 status are unlikely to see meaningful wearable changes from supplementation
- Omega-3 + resistance training coaching is appropriate for older adults; do not position omega-3 as an anabolic aid
- Users on ≥4 g/day should be monitored for AFib, especially those with existing cardiovascular medication regimens
Risks and uncertainty
AFib risk at high dose
At ≥4 g/day EPA (prescription or high-dose OTC), a dose-dependent increase in atrial fibrillation has been observed in REDUCE-IT and STRENGTH. The risk appears real but modest (ARR ~1% absolute). See Omega-3 AFib Risk for full detail.
Drug interactions
| Drug | Issue | Action |
|---|---|---|
| Warfarin | Case reports of elevated INR | Monitor INR when initiating; individual variation |
| DOACs (≤3 g/day) | No strong PK/PD evidence | Clinical judgment; no routine monitoring required |
| Aspirin / clopidogrel + ≥4g EPA | Extended bleeding time | Standard precautions; high-dose + multiple antithrombotics needs clinical judgment |
| Fish / shellfish allergy | Anaphylaxis | Contraindicated — fish protein traces |
Cancer signal (prostate)
SELECT trial found higher omega-3 blood levels associated with increased low-grade (HR=1.44) and high-grade (HR=1.71) prostate cancer. PLCO found dietary omega-3 intake associated with reduced overall prostate cancer risk (HR=0.90). These may differ mechanistically (blood biomarker vs dietary intake). The biological mechanism is not established. Evidence: Contested.
LDL-C elevation
EPA+DHA combination can raise LDL-C (statistically significant in meta-analyses). Monitor lipids when initiating.
No established upper limit
The IOM has not established a Tolerable Upper Intake Level. Doses up to 4 g/day of prescription omega-3 are FDA-approved. Doses >4 g/day require medical supervision.
Best stack context
Inflammation resolution stack
- Omega-3 + curcumin: targets both SPM resolution pathway (Specialized Pro-Resolving Mediators) and NF-κB suppression simultaneously — complementary mechanisms, no safety concerns at standard doses
- Omega-3 + berberine: different anti-inflammatory pathways (membrane/SPM vs AMPK/gut microbiome); potentially complementary for metabolic inflammation
Sarcopenia / strength stack (older adults)
- Omega-3 + resistance training: strength improvement via non-MPS mechanism — PMID:38777432
- Stack with adequate protein (2–2.5 g/kg/day) and Resistance Training for Longevity
- Do not position omega-3 as an anabolic; the synergy is likely neural/mitochondrial
Cardiovascular risk stack (high-TG, statin-treated)
- Omega-3 (prescription pure EPA 4 g/day) + statin: 25% RRR in MACE in selected population (REDUCE-IT)
- Note: OTC fish oil has not demonstrated equivalent outcome benefit
- Monitor for AFib at this dose
What NOT to stack with
- Omega-3 is not a nootropic for cognitively healthy adults — combining with other cognitive enhancers is not supported by evidence
- Do not combine high-dose (>3 g/day) with multiple antithrombotics without clinical supervision
Vitals Protocol Summary
Who should consider omega-3 supplementation
- Individuals with elevated inflammatory markers (CRP >1 mg/L) or autoimmune inflammation (rheumatoid arthritis)
- Those with elevated triglycerides on statin therapy (consider high-dose prescription purified EPA)
- Older adults combining with resistance training (strength synergy, not MPS)
- Vegetarians/vegans: algae oil is equivalent to fish oil at matched doses
Who should avoid
- Fish/shellfish allergy (anaphylaxis risk)
- Those relying on it for muscle building, cognitive enhancement in healthy adults, or primary CVD prevention in general population
Dosing
| Purpose | Dose | Form |
|---|---|---|
| General anti-inflammatory / raising O3I | 1.5–2 g/day EPA+DHA | rTAG fish oil with fatty meal |
| Rheumatoid arthritis NSAID-sparing | ≥2.7 g/day EPA+DHA | Any form with food |
| Raise Omega-3 Index to >8% (baseline 2–4%) | 1.5–2.25 g/day TG form; 2.25–3.25 g/day EE form | rTAG preferred; take with fat |
| High-TG statin-treated (prescription only) | 4 g/day purified EPA | Icosapent ethyl; Rx required |
Quality checklist
- IFOS 5-star certification preferred; GOED/USP acceptable
- rTAG form preferred for bioavailability
- Check mercury/PCB test results on manufacturer website
- Store in refrigerator after opening; avoid oxidation
- Take with largest fatty meal of the day (especially for EE form)
- Algae oil is an equivalent option for vegetarians/vegans
Key monitoring
- Baseline + 4-month Omega-3 Index via finger-prick dried blood spot test (most actionable biometric)
- Baseline lipid panel — EPA+DHA combo can raise LDL-C
- AFib awareness at doses ≥4 g/day (especially with concurrent CV medications)
- Bleeding signs only clinically relevant with concurrent antithrombotics at high dose
Related notes
- Omega-3 Index — the primary biometric for tracking omega-3 supplementation (03-Biometrics)
- Specialized Pro-Resolving Mediators — the unique anti-inflammatory mechanism of omega-3 (02-Mechanisms)
- Omega-3 AFib Risk — dose-dependent AFib risk at ≥4 g/day (04-Protocols-and-Recovery)
- Berberine — complementary AMPK/gut anti-inflammatory pathway
- Curcumin — complementary NF-κB anti-inflammatory pathway
- Creatine — stack-safe; no interaction with omega-3
- HRV — population-dependent HRV improvement; confounds for wearable interpretation
- Sleep architecture — omega-3 improves sleep; wearable-detectable in 74% of studies
- Resistance Training for Longevity — the exercise context in which omega-3 shows strength benefit